接受[177Lu]Lu-DOTA-TATE治疗的胃肠胰神经内分泌肿瘤患者肾功能下降的预测因素
这项回顾性单中心研究纳入178例完成四周期[177Lu]Lu-DOTA-TATE治疗的高分化胃肠胰神经内分泌肿瘤患者,随访时平均eGFR与基线持平,15例(8.9%)出现KDIGO定义的肾功能下降;基线年龄较高与风险增加显著相关(OR 1.07),基线eGFR与估算肾脏辐射剂量均非显著预测因素。
要点
- 178例中15例(8.9%)出现KDIGO定义的肾功能下降(eGFR随访/基线比值<0.8)。
- 基线年龄较高与肾功能下降风险增加显著相关(OR 1.07,95%CI 1.01–1.14,p=0.023)。
- 基线eGFR与估算肾脏辐射剂量均非显著预测因素。
核心结论
- 接受[177Lu]Lu-DOTA-TATE治疗的胃肠胰神经内分泌肿瘤患者总体肾功能下降风险低。
- 在该队列中,基线年龄是简单且具有临床意义的肾功能下降预测因素。
研究设计与样本
- 回顾性单中心研究,纳入178例完成四周期[177Lu]Lu-DOTA-TATE治疗的高分化(1级或2级)胃肠胰神经内分泌肿瘤患者,治疗时间2012年至2023年。
主要发现
- 平均基线eGFR为81.1 ± 16.3 mL/min/1.73 m²,随访时为81.1 ± 17.8 mL/min/1.73 m²(p = 0.989)。
- 15例(8.9%)出现KDIGO定义的肾功能下降(eGFR随访与基线比值<0.8)。
- 基线年龄较高与风险增加显著相关(OR 1.07,95%CI 1.01–1.14,p = 0.023)。
- 基线eGFR(OR 1.03,95%CI 0.99–1.06,p = 0.1)与估算肾脏辐射剂量(OR 1.06,95%CI 0.89–1.21,p = 0.456)均非显著预测因素。
- 既存肾病、动脉性高血压、糖尿病或肾毒性药物均未见显著关联。
关键数值与推荐
- KDIGO定义的肾功能下降:eGFR随访与基线比值<0.8。
- 年龄的ROC分析AUC为0.683,识别出68.77岁为无慢性肾脏病进展生存风险分层的最佳阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE is an established treatment for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). While overall renal safety is high, the kidneys remain an organ at risk. This study aimed to determine whether clinical parameters can predict the risk of PRRT-associated renal function decline. RESULTS: This retrospective single-center study included 178 patients with well-differentiated GEP-NETs (Grade 1 or 2) who completed four cycles of [177Lu]Lu-DOTA-TATE between 2012 and 2023. Mean baseline eGFR was 81.1 ± 16.3 mL/min/1.73 m² and remained stable at follow-up (81.1 ± 17.8 mL/min/1.73 m², p = 0.989). A KDIGO-defined renal function decline (eGFR follow-up to baseline ratio < 0.8) was observed in 15 patients (8.9%). Higher age at baseline was significantly associated with increased risk (OR: 1.07, 95% CI: 1.01–1.14, p = 0.023), while baseline eGFR (OR: 1.03, 95% CI: 0.99–1.06, p = 0.1) and estimated renal radiation dose (eRRD) (OR: 1.06, 95% CI: 0.89–1.21, p = 0.456) were not significant predictors. No significant associations were found for preexisting renal disease, arterial hypertension, diabetes mellitus, or nephrotoxic drugs. ROC analysis yielded an AUC of 0.683 for age, identifying 68.77 years as the optimal threshold for risk stratification of CKD-progression free survival. CONCLUSIONS: While the overall risk of renal function decline following [177Lu]Lu-DOTA-TATE therapy of GEP-NET patients is low, age at baseline emerged as a simple yet clinically meaningful predictor of renal function decline in this cohort.
引用
- Herr FL, Dascalescu C, Fusch V, et al. Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy. EJNMMI Res. 2025. PMID: 40835788. doi:10.1186/s13550-025-01305-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。